Crenolanib (CP-868,596)
Revision as of 17:48, 3 February 2019 by Warner-admin (talk | contribs) (Text replacement - "Category:Investigational" to "Category:Investigational drugs")
In clinical trials
Preliminary Data
- Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. link to original article PubMed